Obesity pillars · 2026
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gibble Theresa Hunter, Leith Andrea, Harrison Lewis, Gerber Claire, Raikar Sonya Kokil, Seth Era, Artime Esther
Аннотация
BACKGROUND: Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated its efficacy in clinical trials; however, real-world evidence on treatment satisfaction and experiences among people with obesity or overweight (PwO) and their prescribing physicians remains limited. This study aimed to assess the real-world clinical characteristics, treatment patterns, and satisfaction with tirzepatide among PwO without type 2 diabetes (T2D) and their prescribing physicians in the United States.
METHODS: This secondary analysis utilized data from a cross-sectional survey of physicians and PwO from October 2023 to April 2024, and from October 2024 to January 2025. Physicians provided data for PwO meeting selection criteria, at data capture/previous body mass index (BMI) ≥30 or ≥27 and < 30 kg/m2 with at least one obesity-related complication (ORC), without T2D, enrolled in a weight management program, and were receiving tirzepatide at the time of data collection. Sociodemographic and clinical characteristics, treatment history, and satisfaction measures were analyzed.
RESULTS: Data from 151 physicians and 199 PwO without T2D using tirzepatide were included. Most PwO (84.4%) had ≥1 ORC, with hypertension and dyslipidemia being the most prevalent. Over 90% (n = 45/48) of PwO reported likelihood to recommend tirzepatide reflecting high satisfaction and willingness to recommend tirzepatide to others. Physicians reported long-term safety, ease of dosing, and reduced appetite as key reasons for prescribing tirzepatide. Physicians reported that tirzepatide treatment was successful in the majority of people (78.5%) being treated for obesity.
CONCLUSIONS: The data in these surveys reflected that PwO without T2D prescribed tirzepatide had high motivation, adherence, and satisfaction. These findings provide real-world insights into treatment and satisfaction with tirzepatide.
METHODS: This secondary analysis utilized data from a cross-sectional survey of physicians and PwO from October 2023 to April 2024, and from October 2024 to January 2025. Physicians provided data for PwO meeting selection criteria, at data capture/previous body mass index (BMI) ≥30 or ≥27 and < 30 kg/m2 with at least one obesity-related complication (ORC), without T2D, enrolled in a weight management program, and were receiving tirzepatide at the time of data collection. Sociodemographic and clinical characteristics, treatment history, and satisfaction measures were analyzed.
RESULTS: Data from 151 physicians and 199 PwO without T2D using tirzepatide were included. Most PwO (84.4%) had ≥1 ORC, with hypertension and dyslipidemia being the most prevalent. Over 90% (n = 45/48) of PwO reported likelihood to recommend tirzepatide reflecting high satisfaction and willingness to recommend tirzepatide to others. Physicians reported long-term safety, ease of dosing, and reduced appetite as key reasons for prescribing tirzepatide. Physicians reported that tirzepatide treatment was successful in the majority of people (78.5%) being treated for obesity.
CONCLUSIONS: The data in these surveys reflected that PwO without T2D prescribed tirzepatide had high motivation, adherence, and satisfaction. These findings provide real-world insights into treatment and satisfaction with tirzepatide.